A Phase 3 interventional study of 90 mg Ticagrelor and 75mg Clopidogrel in Coronary Heart Disease, sponsored by AstraZeneca. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-05-13.
Sponsored by AstraZeneca · Phase 3, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing ticagrelor in Coronary Disease — 2 open to participants now, 2 under way, 1 of them phase 3. Ticagrelor · Coronary Disease.
Among the 12 studies testing ticagrelor in Coronary Disease, this one is the 12th largest by enrollment, is one of 2 that started in 2013, is one of 3 in phase 3, and was the 6th registered.
1,521 studies on the registry are indexed under Coronary Disease; 168 are open to participants now.
Browse Coronary Disease studies →2 of the 12 studies testing ticagrelor in Coronary Disease are open now, in 6 countries. Recruiting first, the newest first:
Weill Medical College of Cornell University · Sites in United States, Austria, Canada and 3 more countries
Ages 18+
Fu Wai Hospital, Beijing, China · Sites in China
Ages 18–80
By country, each count listing its studies:
Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 106 Coronary Disease studies recruiting now, 64 (60%) set no upper age limit and 19 (18%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 2 started in 2013.
Median enrollment 70 across the 12 interventional studies. Of the 6 that completed or were terminated, 3 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 12 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
18 studies in Coronary Disease by AstraZeneca: none open now, none under way, none of them phase 3. Of 17 finished, 5 (29%) have results posted.
Among the 18 studies in Coronary Disease by AstraZeneca, this one is the only one that started in 2013, is one of 6 in phase 3, and was the 14th registered.
AstraZeneca’s Coronary Disease studies by the year they started, since 2001.
1 of the studies testing ticagrelor in Coronary Disease that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05997693Phase 3Weill Medical College of Cornell UniversityOne-Month DAPT in CABG Patients | 2027-01 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing ticagrelor in Coronary Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 18 in Coronary Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study in Vietnamese Patients with Coronary Heart Disease to investigate safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel
Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patients with Coronary Heart Disease: A Randomized, Open Label, Crossover Study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
90 mg Ticagrelor
Drug: 90 mg Ticagrelor
75mg Clopidogrel
Drug: 75mg Clopidogrel
Morning and Evening dose for 5 days
Morning dose for 5 days
Pharmacodynamics of Ticagrelor on P2Y12 receptor blockade measured by the VerifyNow P2Y12 assay[expressed as P2Y12 reaction units (PRU)]
Time frame: Day 1 pre-dose and at 0 (pre-dose), 1, 2, 8, 12 and 24 hours post morning dose on Day 5
Pharmacodynamics of Clopidogrel P2Y12 receptor blockade measured by the VerifyNow P2Y12 assay[expressed as P2Y12 reaction units (PRU)]
Time frame: Day 1 pre-dose and at 0 (pre-dose), 1, 2, 8, 12 and 24 hours post morning dose on Day 5
Safety profile in terms of adverse events, blood pressure, pulse, ECG (Electrocardiogram), physical examination, and safety laboratory variables
Time frame: From screening to followup (8 weeks)
No study locations are listed for this record.
The record gives a start of Jan 2013, a primary completion of Apr 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in May 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ticagrelor